Patients with Complex IBD at Increased Risk of Renal Cell Carcinoma, but with Better Survival Outcomes

Patients with Complex IBD at Increased Risk of Renal Cell Carcinoma, but with Better Survival Outcomes
In a new study entitled “Better survival of renal cell carcinoma in patients with inflammatory bowel disease”, researchers investigated whether the commonly used immunosuppressive and anti-TNFα therapies in inflammatory bowel disease (IBD) affect a patients' risk to develop cancer, especially renal cell carcinoma (RCC). The study was published in the journal Oncotarget. IBD comprises a group of diseases characterized by chronic inflammation of the gastrointestinal tract, with Crohn's disease (CD) and Ulcerative Colitis (UC) as the two main types of IBD. Treatment of IBD may include the use of immunosuppressive medication (drugs that suppress the immune system), although this type of medication, together with the intrinsic inflammatory status of IBD, has led IBD patients more susceptible to other intestinal and non-intestinal malignancies. Particularly, due to IBD patients’ need for a long-term use of immunosuppressants, the risk for cancer such as RCC is a concern growing among the IBD research field. However, current data regarding the risk for IBD patients to develop RCC is lacking. The research team investigated the risk factors for RCC development, and compared IBD patients and the general population for RCC characteristics, outcome and survival. To this end, the
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *